Company Profile

Aqualung Therapeutics Corporation
Profile last edited on: 4/25/2022      CAGE: 67FD4      UEI: MKDKZ3ZZ99A2

Business Identifier: Anti-inflammatory monoclonal antibody strategy to treat serious unchecked inflammation.
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

1790 East River Suite 205
Tucson, AZ 85718
Location: Single
Congr. District: 06
County: Pima

Public Profile

Focused on in patient disorders characterized by acute and chronic lung and systemic inflammation, Aqualung Therapeutics is an early stage biotech company developing immune-focused therapeutic antibodies: innovative tools are designed to prevent, diagnose and treat fluid accumulation in the lungs or pulmonary edema for inflammatory lung disorders that include acute lung injury, asthma, pulmonary hypertension, sarcoidosis, idiopathic pulmonary fibrosis and lung complications of sickle cell disease. The firm's science-driven approaches had earlier led them to the identification of nicotinamide phosphoribosyltransferase (NAMPT) and other key proteins expressed in both acute and chronic lung inflammatory diseases - all conditions representing an unnet medical need with significant morbidity and mortality.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Key People / Management

  Joe "skip" G N Garcia -- Founder and Chief Executive Officer

  Stan Miele -- President and Chief Business Officer

  Sara M Camp -- Director of Operations

  Eddie Chiang -- former Chief Executive Officer

  Joe G N Garcia

  Mariam Morris -- Chief Financial Officer (Advisor)